AstraZeneca is trading at $189.45 (+3.03%) amid a broader U.S. market rally and healthcare-sector strength; available reports point mainly to sector and market sentiment, not a confirmed company-specific catalyst. - Healthcare rose 1.37%; reports also describe strength among pharmaceutical shares amid changing views on U.S. drug-pricing policy, though election-policy explanations are mixed. - AstraZeneca’s latest earnings and outlook were reported October 30; available reports identify no clear new company-specific catalyst for the November 4 move.